Cargando…

Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia

A 36-year-old woman with decompensated liver cirrhosis type C was referred to our hospital to receive antiviral treatment for hepatitis C virus (HCV). She had been diagnosed with intractable epilepsy and cerebral palsy at birth and was managed by central venous nutrition and nasal gastric feeding. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murayama, Aiko, Tajiri, Kazuto, Kanegane, Chiharu, Murakami, Jun, Hayashi, Yuka, Yasuda, Ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436629/ https://www.ncbi.nlm.nih.gov/pubmed/34594173 http://dx.doi.org/10.1159/000518306

Ejemplares similares

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir
por: Tarao, Kazuo, et al.
Publicado: (2021)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
por: Flamm, Steven, et al.
Publicado: (2023)

Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis
por: Kotani, Kohei, et al.
Publicado: (2023)

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
por: Suzuki, Naomi, et al.
Publicado: (2020)

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
por: Takehara, Tetsuo, et al.
Publicado: (2018)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
por: Heo, Jeong, et al.
Publicado: (2023)

Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis
por: Shah, Islam, et al.
Publicado: (2021)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
por: Childs-Kean, Lindsey M, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection
por: Anna, Linda Zignego, et al.
Publicado: (2018)

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
por: Ren, Xiao-Dan, et al.
Publicado: (2022)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China
por: Abulitifu, Yilihamu, et al.
Publicado: (2022)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
por: Tajiri, Kazuto, et al.
Publicado: (2023)

An Autopsy Case of Ruptured Hepatic Angiosarcoma Treated by Transcatheter Arterial Embolization
por: Entani, Toshiki, et al.
Publicado: (2023)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
por: Huang, Yu-Ting, et al.
Publicado: (2021)

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
por: Liu, Chen-Hua, et al.
Publicado: (2021)

Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
por: Loo, Jing Hong, et al.
Publicado: (2022)

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020)

Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
por: Liu, Hui, et al.
Publicado: (2016)

Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
por: Ahmed, Rowan, et al.
Publicado: (2021)

Achieving the Sustained Virologic Response With a Short-Course Treatment of Sofosbuvir/Velpatasvir
por: Abi-Saleh, Simon P, et al.
Publicado: (2023)

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
por: Atsukawa, Masanori, et al.
Publicado: (2020)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial
por: Butt, Nazish, et al.
Publicado: (2020)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Selective and sensitive spectrofluorimetric quantification of velpatasvir in presence of sofosbuvir. Application to their co-formulated tablet
por: El-Gamal, Rania M., et al.
Publicado: (2018)

Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India
por: Bloom, David E., et al.
Publicado: (2021)

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
por: Cardona‐Gonzalez, Maria G., et al.
Publicado: (2018)

Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19
por: Messina, Vincenzo, et al.
Publicado: (2022)

Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization
por: Kobayashi, Saito, et al.
Publicado: (2020)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
por: Murayama, Aiko, et al.
Publicado: (2021)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
por: Al Moussawi, Hassan, et al.
Publicado: (2018)

Vanishing Tumor in a Liver Graft from a Hepatitis B Virus Surface Antigen-Positive Donor
por: Fuchino, Mayo, et al.
Publicado: (2017)

Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China
por: Zhang, Hedong, et al.
Publicado: (2022)

Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis
por: Shahid, Salman, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0h5reqfic3m1eq37iaq64on4pa